3 Stocks Pushing The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average (^DJI) trading down 17 points (-0.1%) at 12,949 as of Tuesday, Nov. 27, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,707 issues advancing vs. 1,183 declining with 148 unchanged.

The Drugs industry currently sits up 0.8% versus the S&P 500, which is up 0.0%. A company within the industry that increased today was ACADIA Pharmaceuticals (ACAD), up 151.7%. On the negative front, top decliners within the industry include Vertex Pharmaceuticals (VRTX), down 0.9%, and Gilead (GILD), down 0.5%.

TheStreet Ratings group would like to highlight 3 stocks pushing the industry higher today:

3. Dr. Reddy Laboratories (RDY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Dr. Reddy Laboratories is up $0.57 (1.8%) to $32.57 on light volume Thus far, 58,679 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 221,500 shares. The stock has ranged in price between $32.19-$32.60 after having opened the day at $32.44 as compared to the previous trading day's close of $32.00.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $5.4 billion and is part of the health care sector. The company has a P/E ratio of 19.3, above the S&P 500 P/E ratio of 17.7. Shares are up 8.7% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Dr. Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Dr. Reddy Laboratories Ratings Report now.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

1 2 3 Next › Last »

For more information on Teva Pharmaceutical Industries Ltd click any of the following:

• Teva Pharmaceutical Industries Ltd Stock Price

• Teva Pharmaceutical Industries Ltd Analyst Ratings

• Teva Pharmaceutical Industries Ltd Key Stats & Profile

• Teva Pharmaceutical Industries Ltd Earnings

• Teva Pharmaceutical Industries Ltd Ratio Comparison

• Teva Pharmaceutical Industries Ltd Growth Rates

• Teva Pharmaceutical Industries Ltd Balance Sheet

• Teva Pharmaceutical Industries Ltd Cash Flow

• Teva Pharmaceutical Industries Ltd Income Statement